Business
Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc
— Dr. Loew to Assume New Leadership Role Upon Completion of the Planned Separation of Alkermes' Oncology Business — — Planned Separation Remains on Track to
About this update from Alkermes Plc
[{"type":"text","content":"— Dr. Loew to Assume New Leadership Role Upon Completion of the Planned Separation of Alkermes' Oncology Business —\n— Planned Separation Remains on Track to be Completed in Second Half of 2023 —\nDUBLIN, June 1, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent public company to be established upon the planned separation of Alkermes' oncology business. Dr. Loew will join Alkermes in June as a strategic advisor and transition to CEO of Mural Oncology upon completion of the separation. \n\"Dr. Loew's deep knowledge of the oncology field, extensive leadership experience, and strong track record of execution and strategic business development initiatives make her uniquely qualified to lead Mural Oncology when it begins its journey as a new and independent company,\" said Richard Pops, CEO of Alkermes. \"I'm delighted that we have appointed someone of Dr. Loew's caliber and scientific pedigree for the Mural Oncology CEO role. We continue to believe that nemvaleukin alfa, our novel, investigational, engineered IL-2 variant, represents a significant potential medical and economic opportunity, and I am confident that Dr. Loew will provide strong leadership for Mural Oncology as it advances the nemvaleukin development program and other pipeline assets.\"\n\"I am thrilled to have the opportunity to lead Mural Oncology as it establishes itself as an independent company,\" said Dr. Caroline Loew. \"Anchored by the potential of nemvaleukin, a late-stage and potential first-in-class cancer immunotherapy, Mural Oncology has a unique opportunity as a new company focused on the development of novel treatments for difficult-to-treat tumor types. I look forward to partnering with Alkermes to build the Mural Oncology team, engage with the investor community, and work towards completing the separation in the second half of the year.\"\nDr. Loew's biopharmaceutical career spans over 25 years of drug development and commercialization experience. She most recently served as President and CEO at Glympse Bio (Glympse), a biotechnology company based in Cambridge, Mass. Prior to Glympse, Dr. Loew was Vice President, Head of R&D Strategy and Planning at Bristol-Myers Squibb (BMS). At BMS, she l...